A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations

Pruthi, Sandhya; Boughey, Judy C.; Brandt, Kathleen R.; Degnim, Amy C.; Dy, Grace K.; Goetz, Matthew P.; Perez, Edith A.; Reynolds, Carol; Schomberg, Paula J.; Ingle, James N.

doi:10.4065/82.9.1131

Cited by 28 publications

(20 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,33 Hyperdiploid myeloma is characterized by trisomies of various odd-numbered chromosomes, especially 3, 5, 7, 9, 11, 15, 19, or 21, and is observed in 50% to 60% of patients. [46][47][48][49][50] In contrast, the nonhyperdiploid group (40%-50% of patients) typically has translocations involving the immunoglobulin heavy chain locus on chromosome 14. 43 The translocations can involve different partner chromosomes, leading to activation of oncogenes; the sites (genes) typically involved are 11q13 (CCND1), 6p21 (CCND3), 16q23 (MAF), 20q12 (MAFB), and 4p16 (FGFR3 and MMSET).…”

Section: Risk Stratification Of Newly Diagnosed MMmentioning

confidence: 99%

“…Similar recommendations have been put forth by Mayo Clinic physicians to guide treatment of other cancers. [9][10][11][12][13][14][15][16][17][18][19][20] When specific evidence is lacking, our group of 21 Mayo Clinic myeloma experts reached a consensus based on current practice patterns. The preferential use of oral vs intravenous therapies, when evidence does not conclusively favor one over the other, is largely a function of our practice pattern, rather than any implied statement about differences in efficacy.…”

Section: Management Of Newly Diagnosed Symptomatic Multiple Myeloma: mentioning

confidence: 99%

See 1 more Smart Citation

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Mıkhael

Dingli

Roy

et al. 2013

Mayo Clinic Proceedings

453

393

View full text Add to dashboard Cite

Section: Risk Stratification Of Newly Diagnosed MMmentioning

confidence: 99%

Section: Management Of Newly Diagnosed Symptomatic Multiple Myeloma: mentioning

confidence: 99%

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Mıkhael

Dingli

Roy

et al. 2013

Mayo Clinic Proceedings

453

393

View full text Add to dashboard Cite

“…This may be explained in part by better established and more comprehensive recommendations for adjuvant hormonal therapy use during this period. 7,8,18 It was not until 1998 that the Early Breast Cancer Trialists' Collaborative Group published findings confirming the efficacy of tamoxifen for both premenopausal and postmenopausal women exclusively for hormone receptorpositive tumors. 8 Over the last decade, aromatase inhibitors 956 LIVAUDAIS ET AL.…”

Section: Discussionmentioning

confidence: 99%

Racial and Ethnic Differences in Adjuvant Hormonal Therapy Use

Livaudais

John

et al. 2012

Journal of Women's Health

View full text Add to dashboard Cite

Background: In the United States, 5-year breast cancer survival is highest among Asian American women, followed by non-Hispanic white, Hispanic, and African American women. Breast cancer treatment disparities may play a role. We examined racial/ethnic differences in adjuvant hormonal therapy use among women aged 18-64 years, diagnosed with hormone receptor-positive breast cancer, using data collected by the Northern California Breast Cancer Family Registry (NC-BCFR), and explored changes in use over time. Methods: Odds ratios (OR) comparing self-reported ever-use by race/ethnicity (African American, Hispanic, non-Hispanic white vs. Asian American) were estimated using multivariable adjusted logistic regression. Analyses were stratified by recruitment phase (phase I, diagnosed January 1995-September 1998, phase II, diagnosed October 1998-April 2003) and genetic susceptibility, as cases with increased genetic susceptibility were oversampled. Results: Among 1385 women (731 phase I, 654 phase II), no significant racial/ethnic differences in use were observed among phase I or phase II cases. However, among phase I cases with no susceptibility indicators, African American and non-Hispanic white women were less likely than Asian American women to use hormonal therapy (OR 0.20, 95% confidence interval [CI]0.06-0.60; OR 0.40, CI 0.17-0.94, respectively). No racial/ ethnic differences in use were observed among women with 1 + susceptibility indicators from either recruitment phase. Conclusions: Racial/ethnic differences in adjuvant hormonal therapy use were limited to earlier diagnosis years (phase I) and were attenuated over time. Findings should be confirmed in other populations but indicate that in this population, treatment disparities between African American and Asian American women narrowed over time as adjuvant hormonal treatments became more commonly prescribed.

show abstract

“…Additional supplementary treatment in the form of radiotherapy is applied after the procedure in order to reduce the risk of topical recurrence of the tumour as much as possible. Irradiation combined with breast-conserving surgery can be applied to the whole mammary gland or limited to the area where the tumour was removed [2,4]. However, radiotherapy used in treatment of invasive forms of breast cancer usually takes the form of palliative care.…”

Section: Original Papersmentioning

confidence: 99%

“…Additionally, the occurrence of metastatic foci in organs distant from the primary tumour requires, in many cases, a systemic approach to treatment, which includes both chemotherapy and hormonal therapy [1]. None of the available methods is fully efficient and some patients who underwent radical treatment still suffer from recurrences [2,4].…”

Section: Original Papersmentioning

confidence: 99%

Expression of Proapoptotic BAX and TP53 Genes and Antiapoptotic BCL-2 Gene in MCF-7 and T-47D Tumour Cell Cultures of the Mammary Gland After a Photodynamic Therapy with Photolon

Płonka¹,

Latocha²,

Kuśmierz³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Breast cancer is the most common malignant tumour in women in the whole world. Despite significant developments in the early diagnosis of breast cancer, there is no effective method which would assure total recovery of the patient. Currently available clinical data and laboratory tests indicate a possibility to introduce photodynamic therapy (PDT) to the supplementary treatment of breast cancer. Objectives. The aim of this study was to assess the influence of PDT with Photolon as a photosensibilizator on the expression of apoptosis associated genes (BCL-2, BAX, TP53) in human breast cancer cell lines, preceded by assessment of survivorship and proliferative activity in the tested cells after PDT. Material and Methods. In the present study human breast cancer cell lines MCF-7 and T-47D were used. Photolon (chlorin e6 complex: PVP 1:1) was used as a photosensitizer. Assessments of survivorship and proliferative activity of cells under the influence of PDT (WST-1 test) were conducted along with the expression of selected genes involved in the process of apoptosis: BCL-2, BAX, TP53 (RT-QPCR). Results. PDT limited both survivorship and proliferative activity of breast cancer cells in the two tested lines. In case of T-47D cell line was found increase of BAX and BCL-2 genes expression after PDT and sustained activity of TP53 gene. Conversely, in MCF-7 cell line a decrease in expression was found for both BAX and TP53 genes, but also an increase of BCL-2 gene expression. Conclusions. A progressing decrease (24, 48 and 72 h after PDT) in the count of culture cells, which suggests the occurrence of apoptosis initiated by a photodynamic reaction with simultaneous increase of BCL-2/BAX index, indicates activation of a different endogenous apoptosis pathway than the one examined, namely pointing to sui-

show abstract

A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations

Cited by 28 publications

References 79 publications

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Racial and Ethnic Differences in Adjuvant Hormonal Therapy Use

Expression of Proapoptotic BAX and TP53 Genes and Antiapoptotic BCL-2 Gene in MCF-7 and T-47D Tumour Cell Cultures of the Mammary Gland After a Photodynamic Therapy with Photolon

Contact Info

Product

Resources

About